NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
PR Newswire•09/11/2026•16:00 ET
0
Key Highlights
- ➤Repatha cost-effective at approximately 36% below the ACC/AHA benchmark
- ➤Repatha lowered 3-P MACE by 39% in CKD patients without prior events
- ➤Repatha associated with 29% lower 3-P MACE rate over more than eight years
- ➤Repatha reduced cardiovascular death risk by 25% versus an external control
- ➤VESALIUS-CV previously showed 25% lower 3-P MACE risk without prior events
Expert Statements
Murdo Gordon, Executive Vice President of Global Markets and Policy at Amgen
“In the U.S., every 40 seconds someone has a heart attack and three out of four of those are first-time events. With more than a decade of clinical research with Repatha and growing evidence supporting earlier LDL-C lowering, no one should have to wait for a first heart attack or stroke to take more aggressive action against cardiovascular risk”
Murdo Gordon, Executive Vice President of Global Markets and Policy at Amgen
“For high-risk patients with a guideline recommended LDL-C goal below 55 mg/dL, we need to help make reaching that goal sooner a reality. That means pairing strong clinical data with continued efforts to address barriers to care. We've taken actions to make Repatha more affordable and accessible, and these findings add to the evidence of its benefit to patients.”
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM PR Newswire
Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke
Get started
Create a free account to read the full story.